RGC Stock — Regencell Bioscience Holdings Ltd

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.0%

Year over year · more shares

Price change (1Y)

-60.1%

Trailing year

Short interest

0.1%

Latest settlement · 7.3 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.2 · calm Equity put/call 0.62

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −61%

below

Price vs 50-day avg +23%

above

RSI (14) 64

neutral

MACD trend Positive

52-week position 5%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +30%

trailing

6-month return −74%

trailing

YTD return −65%

this year

Relative strength −84%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $6 › 200d $19 — 200d above 50d

Institutional flow Accumulating

+6% holders QoQ · +14 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.13% of float · ▼ -18.1% MoM · 7.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

36 holders — near 3-yr high, broad support

Squeeze score 53

elevated · 0–100

Fundamentals

Poor

EPS growth −229%

Y/Y

Free cash flow $-7.8M

Quant / Vol

risk profile

Very High

Volatility 145%

annualized · 1-yr

Max drawdown −91%

past year

ATR 7.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−61% Bearish

Price vs 50-day avg

+23% Bullish

RSI (14)

64 Neutral

MACD trend

Positive Bullish

52-week position

5% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $6 › 200d $19 — 200d above 50d

Institutional flow Accumulating

+6% holders QoQ · +14 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.13% of float · ▼ -18.1% MoM · 7.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

36 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $5 Now $7 · 5% Range high $53

vs 200-day avg -61% vs 50-day avg +23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RGC Regencell Bioscience Holdings Ltd this stock	$3.64B	-65.0%	—	—	0.1%
TAK Takeda Pharmaceutical Co Ltd	$59.83B	+19.8%	—	—	0.1%
TEVA Teva Pharmaceutical Industries Ltd	$47.89B	+31.7%	+4.3%	67.4	2.6%
GALDY Galderma Group AG/ADR	$46.88B	-4.0%	—	—	0.0%
HLN Haleon plc	$41.78B	-7.8%	—	—	0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

36

% held: 0.3%
Net QoQ: +825.3K sh
Top holder: GEODE CAPITAL MANAGEMENT,…

Held Float

View

Held by Funds

Fund positions

1

View

Short & Settlement

Short Interest Falling

Shares short

656.2K

Days to cover: 7.3d
Change: -145.1K sh

View

Short Volume

Short vol %

51%

As of: Oct 12, 2026

Short Total

View

Fails to Deliver

FTD shares

18.4K

Value: $103.8K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

43.3%

Week of: Sep 7, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-11.7M

EPS diluted: $-2.37

View

Filings

SEC Filings

Latest

20-F

Filed: Oct 7, 2026
This year: 9

View

	5D	20D	120D	MTD	YTD
RGC	+7.8%	+30.3%	-73.8%	+18.2%	-65.0%
SPY	+1.2%	+1.9%	+9.9%	+2.1%	+14.2%
vs SPY	+6.6%	+28.5%	-83.7%	+16.1%	-79.2%

RGC · Regencell Bioscience Holdings Ltd

Price & Indicators

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance